Make your money go further for just 25p per day

PREMIUM

Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · AstraZeneca (AZN)  · Compass (CPG)  · Diageo PLC (DGE)  · GlaxoSmithKline (GSK)  · Next (NXT)  · Persimmon (PSN)  · Relx (RELX)  · Unilever (ULVR) 

Dividends FTSE 100 Investment Ideas UK

Relx logo on board in headquarters

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies which might follow Vodafone’s lead and cut their pay-outs. But the stocks whose dividends you can rely on come with an added valuation risk which investors might want to avoid.


In part one of our mini-series on dividends, we looked at the FTSE 100 companies which are likely to follow Vodafone’s lead and cut their dividends in 2019. We suggested that a yield of over 8% is a major red flag for investors considering the future of their income.

But if you’re going to dump the dividend dogs out of fear of a cut, where should you re-invest your money if you want to continue to receive a generous income?

That’s a tricky question to answer because many of the UK’s more reliable dividend stocks are very expensive, meaning the yield barely offers you any more than what you would get from putting your money into government bonds.

Take Relx (LON: REL)Diageo (LON: DGE) and Compass (LON: CPG) for example. These quality companies have forecast dividend yields of 2.5%, 2.1% and 2.3% respectively. That compares to current 10-year yields on government bonds of 1.1% in the UK and 2.4% in…

Continue reading this article…

Enjoy FREE access to the top news and insights from the investment world and our introductory finance guides.
  • Informative guides
  • Unique podcasts
  • Financial news and political insight
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • In depth coverage of many of the world’s great companies
  • Breaking news on potential upcoming disasters
  • Unique insights from our top research team

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world

REGISTER FREE TODAY

Become a Champion Investor for as little as £3.20 per report or get a year's worth of money-making analysis for just £90.

SUBSCRIBE NOW

More on AstraZeneca

The week at a glance: 22 July – results madness

26/07/2019 · News & Insights

Who says 38-degree heat isn’t the perfect temperature for analysing company results? For those who didn’t…


Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Astra vs GSK. Drugs vs Dividends.

16/11/2018 · News & Insights
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More on Compass

Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


More on Diageo PLC

The week at a glance: 5 August – fallen short

09/08/2019 · News & Insights

One story that has dominated the headlines for UK investors this week is the almighty collapse…


Diageo targets teetotallers

07/08/2019 · Portfolio Flash News

Diageo is in our portfolio because it has defensive qualities which can support it even in…


The week at a glance: 22 July – results madness

26/07/2019 · News & Insights

Who says 38-degree heat isn’t the perfect temperature for analysing company results? For those who didn’t…


Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Portfolio Flash News: April

30/04/2019 · Portfolio Flash News

It’s not always easy to keep track of your investments. Sometimes big news gets hidden in…


More on GlaxoSmithKline

The week at a glance: 22 July – results madness

26/07/2019 · News & Insights

Who says 38-degree heat isn’t the perfect temperature for analysing company results? For those who didn’t…


Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Should investors be worried about social consciousness?

28/03/2019 · Investors Clinic
ESG (environmental, social and governance) investing is becoming increasingly popular, especially amongst young people. So, does…

New Year, new you: profit from your resolutions

07/01/2019 · Investors Clinic
This January, thousands of us will drag ourselves into the gym, or spend our days craving…

GlaxoSmithKline split: a winning strategy?

19/12/2018 · Companies Analysed

Shareholders seem to like the GSK split proposal, with the price up strongly off the back…


More on Next

Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Fast-fashion is an ethical nightmare

28/03/2019 · Company research

Brexit: ten stocks to prepare your portfolio

09/03/2019 · Investors Clinic

With one month to go, businesses are still worried about the potential of leaving the EU…


Cyber Monday: what does it mean for your investments?

26/11/2018 · Companies Analysed
Today is the biggest online sales day of the year. Sales over the long weekend -…

Sosandar – bonkers valuation of the week….again!

23/11/2018 · News & Insights
Our blog from October 2018 commented on the crazy valuation the stock market has decided to…

More on Persimmon

How are the housebuilders coping with the UK property market?

11/07/2019 · Investors Clinic

The share prices of many of the UK’s major housebuilders suggest that investors are wary about…


The week at a glance: 1 July – economics and cream

05/07/2019 · News & Insights

Welcome to the first instalment of the Investor’s Champions weekly business round-up. Every Friday we will…


Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Dividend dogs vs diamonds: Part 1 – beware the yield

21/05/2019 · Investors Clinic

A high yielding dividend might be very tempting to investors seeking a little extra income, but…


Michelmersh is an ideal stock: yield, growth and IHT qualifying

26/04/2019 · Investors Clinic

Established in 1997, Michelmersh Brick Holdings (LON:MBH) comprises six of the UK’s premium brands of…


More on Relx

The week at a glance: 22 July – results madness

26/07/2019 · News & Insights

Who says 38-degree heat isn’t the perfect temperature for analysing company results? For those who didn’t…


Relx: Data growth engine drives reliable Relx

25/07/2019 · Portfolio Flash News

Reliable Relx is in our portfolio because it ticks all the boxes: decent growth, strong cash…


Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Portfolio Flash News: May

20/05/2019 · Portfolio Flash News

It’s not always easy to keep track of your investments. Sometimes big news gets hidden in…


Reliable Relx is a portfolio essential

13/03/2019 · Portfolio

Very few British companies tick all the requirements of the Investor’s Champion portfolio: decent growth, strong…


More on Unilever

The week at a glance: 22 July – results madness

26/07/2019 · News & Insights

Who says 38-degree heat isn’t the perfect temperature for analysing company results? For those who didn’t…


Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Investors Clinic

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


Brexit: ten stocks to prepare your portfolio

09/03/2019 · Investors Clinic

With one month to go, businesses are still worried about the potential of leaving the EU…


Brexit means: economic meltdown/trade freedom (delete as applicable)

06/12/2018 · Money Management
A run-through of the most (and least) helpful advice for your finance and investment in the…

Measuring the markets: when not to panic

09/11/2018 · Money Management
It has been a far quieter week for stock market investors, but nerves are still on…

More Investors Clinic

Battle of the booze: how to benefit from a battered market

14/08/2019 · C&C · Molson Coors

Do non-executive directors really add value to smaller quoted companies?

Taylor Wimpey vs Lennar: is there more value in a US housebuilder?

08/08/2019 · Lennar · Taylor Wimpey